Bharat Biotech Dossier Under Review For Covaxin Emergency Use Listing WHO

World Health Organisation (WHO) had a meeting with those of Bharat Biotech and the Hyderabad-based vaccine maker's dossier for Emergency Use Listing (EUL) of Covaxin is under review by the technical experts for consideration, Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia said on Monday.Speaking to ANI, Dr Singh also informed that India has been offered 7.5 million doses of Moderna vaccine through WHO's COVID-19 Vaccines Global Access (COVAX) program.The WHO Regional Director said, "Pfizer, AstraZeneca, Moderna, Johnson and Johnson, Sinovac and Sinopharm have been granted EUL by the WHO. For COVXIN, an expression of interest for EUL has been made to WHO by Bharat Biotech. WHO has already conducted a pre-submission meeting with the company following which a dossier has been submitted by Bharat Biotech to WHO in early July. The dossier is currently under review by the technical experts for consideration of EUL." Cautioning about the possibility of the Delta variant of coronavirus becoming the most dominant COVID strain, Dr Singh said, "Delta variant has spread to over 100 countries, the way its spreading is likely to soon become the most dominant COVID strain globally.""Among all variants of concern, Delta spreads most rapidly. The rapid spread means more cases, leading to more pressure on health systems and more deaths," she said.The WHO South-East Asia director noted that globally, COVID cases and fatalities were again on the rise."The more we allow the virus to spread, the more it will evolve, resulting in more variants. We need to ensure that public health and social measures are implemented continuously. The interventions proven to be effective even against the delta variant," she said.Dr Singh also urged people to act 'urgently' to contain the spread of the COVID-19 virus and aggressively scale up vaccination especially of the vulnerable population for containment of the possible third wave."People are longing to go back to their normal lives which is understandable. However, we have to be reminded of the huge risk of letting our guards down. We witnessed that very recently and continue to do so globally even today. If we take the precautions, get vaccinated and leave no room for the virus to infect us, all of us together can contain the spread of the virus," she noted. She further informed that for the past ten consecutive weeks, COVID cases have been continuously increasing in some Eastern Mediterranean, European and Southeast Asian countries.Dr Singh also noted that cases are on a decline in India, Nepal, and Maldives. "However, the situation continues to be a concern,' she said."The pandemic isn't over anywhere. We must continue to strengthen our capacity. There is absolutely no room for complacency. We need to prevent another surge and scale up our response capacity along with our vaccination programmes," she added.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!